BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine - STAT

SAN FRANCISCO — When BioNTech was founded successful 2008, messenger RNA therapies and vaccines were inactive an unproven idea. The German institution has present shipped retired billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders accidental that’s conscionable the opening of a larger gyration successful medicine.

CEO Uğur Şahin sat down with STAT during this week’s J.P. Morgan Healthcare Conference to speech astir however mRNA — with a spot of assistance from artificial quality — tin powerfulness personalized treatments. Some of this enactment is already happening, including 4 bespoke crab vaccines the institution is investigating successful objective trials. Other efforts are connected the horizon, specified arsenic a caller commitment by BioNTech and the U.K. authorities to dainty arsenic galore arsenic 10,000 patients with personalized mRNA crab immunotherapies by 2030.